Wen-ming Chen

Wen-ming Chen


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2019 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
ZZZhiyao Zhang
Zhiyao Zhang
YLYan‐Chen Li
Yan‐Chen Li
CGChuan‐Ying Geng
Chuan‐Ying Geng
HZHui‐Xing Zhou
Hui‐Xing Zhou
WGWen Gao
Wen Gao
WCWen-ming Chen
Wen-ming Chen

19 March 2009 in The Anatomical Record
Verified
Journal Article
Open access
PDF file
QWQing‐Tao Wang
Qing‐Tao Wang
YLYong‐Zhe Li
Yong‐Zhe Li
YLYu‐Fang Liang
Yu‐Fang Liang
CHChao‐Jun Hu
Chao‐Jun Hu
YZYu‐Hua Zhai
Yu‐Hua Zhai
YXYang Xu
Yang Xu
A diagnosis of multiple myeloma (MM) is difficult to make on the basis of any single laboratory test result. Accurate diagnosis of MM generally results from a number of costly and invasive laboratory tests and medical procedures. The aim of this work is to find a new, highly specific and sensitive method for MM diagnosis. Serum samples were tested in groups representing MM (n = 54) and non‐MM (n = 108). These included a subgroup of 17 plasma cell dyscrasias, a subgroup of 17 reactive plasmacytosis, 5 B cell lymphomas, and 7 other tumors with osseus metastasis, as well as 62 healthy donors as controls. Bioinformatic calculations associated with MM were performed. The decision algorithm, with a panel of three biomarkers, correctly identified 24 of 24 (100%) MM samples and 46 of 49 (93.88%) non‐MM samples in the training set. During the masked test for the discriminatory model, 26 of 30 MM patients (sensitivity, 86.67%) were precisely recognized, and all 34 normal donors were successfully classified; patients with reactive plasmacytosis were also correctly classified into the non‐MM group, and 11 of the other patients were incorrectly classified as MM. The results suggested that proteomic fingerprint technology combining magnetic beads with MALDI‐TOF‐MS has the potential for identifying individuals with MM. The biomarker classification model was suitable for preliminary assessment of MM and could potentially serve as a useful tool for MM diagnosis and differentiation diagnosis. Anat Rec, 292:604–610, 2009.

19 December 2012 in Oncology Letters
Verified
Journal Article
Open access
PDF file
CGChuanying Geng
Chuanying Geng
NLNian Liu
Nian Liu
GYGuangzhong Yang
Guangzhong Yang
MQMan Qi
Man Qi
WCWen-ming Chen
Wen-ming Chen
Myelolipoma is a rare, benign neoplasm composed of mature adipocytes and hematopoietic tissue, mainly occurring in the adrenal glands. The majority of extra-adrenal myelolipomas have been identified in the presacral region and primary mediastinal myelolipoma is very rare. Computed tomography (CT) and magnetic resonance imaging (MRI) are effective methods to detect myelolipoma, while fine-needle aspiration (FNA) combined pathology is able to definitively rule out malignancy. There is no standard method of treatment for the disease. Small (7 cm) myelolipomas should be removed by surgery. This study describes a patient who presented with two mediastinal myelolipomas that were not encapsulated and presented as a string-of-pearls-type. The pathological diagnosis was myelolipoma and the patient did not relapse within the three years following resection.

4 January 2019 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
WGWen Gao
Wen Gao
JLJie Li
Jie Li
YWYin Wu
Yin Wu
YLYanchen Li
Yanchen Li
YLYun Leng
Yun Leng
WCWen-ming Chen
Wen-ming Chen

5 July 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MSMan Shen
Man Shen
GYGuangzhong Yang
Guangzhong Yang
XLXin Li
Xin Li
CGChuanying Geng
Chuanying Geng
ZHZhongxia Huang
Zhongxia Huang
WCWen-ming Chen
Wen-ming Chen
We retrospectively studied the impact of cytogenetic abnormalities in 328 consecutive newly diagnosed multiple myeloma (MM) patients. High-risk cytogenetic abnormalities (HRCAs) included del (17p), amp/gain (1q21), t(4;14), and t(14;16). We defined a standard-risk group by the absence of HRCA, an intermediate-risk group with one HRCA, and a high-risk (HiR) group with at least two HRCAs. The HiR group constituted 14.3% of patients and was associated with a median overall survival (OS) of 28.6 months and progression-free survival (PFS) of 14.0 months. Moreover, the HiR group predicted poor outcomes for OS and PFS in multivariate analyses, and bortezomib prolongation to nine cycles could not bring additional benefit to this entity, suggesting the necessity of more effective therapies for these patients. Furthermore, we confirmed the independent prognostic impact of amp 1q21 in this real-world study.

9 November 2012 in Oncology Letters
Verified
Journal Article
Open access
PDF file
CGChuanying Geng
Chuanying Geng
NLNian Liu
Nian Liu
GYGuangzhong Yang
Guangzhong Yang
ALAijun Liu
Aijun Liu
YLYun Leng
Yun Leng
WCWen-ming Chen
Wen-ming Chen
Multiple myeloma (MM) is the second most common hematological malignancy in China. However, there are only a small number of large cohort studies demonstrating the clinical features of newly diagnosed MM. In the present study, 264 newly diagnosed MM patients from the Beijing Chaoyang Hospital were retrospectively analyzed. The median patient age was 59 years (range, 28‑84) and the most common monoclonal protein (42%) was the IgG subtype. Of the 49 patients detected by FISH, 10.2, 2.0 and 12.2% demonstrated del(17p), t(14;16) and t(4;14), respectively. In total, 228 (86%) patients achieved either a complete response (CR), a very good partial response (VGPR) or a partial response (PR). The overall response rate (ORR) in non-autologous stem cell transplantation (non‑ASCT) patients was 83.0%, with 48 (18.2%), 7 (2.7%) and 121 (45.8%) patients achieving CR, VGPR and PR, respectively. ASCT patients achieved at least a PR prior to ASCT, and ASCT was not able to increase the ORR (P=0.55). Non‑ASCT patients who received bortezomib-based regimens demonstrated an improved ORR compared with those who received regimens that did not contain bortezomib (92.3% vs. 75.8%; P<0.05). With a median follow-up time of 20 months, the estimated median progression-free survival (PFS) and overall survival (OS) times were 27.6 and 61.0 months, respectively. The OS time of patients with high-risk cytogenetic abnormality, del(17p), t(14;16) and t(4;14), was shorter compared with that of other patients (30.2 months vs. not reached, P=0.029). Patients who achieved a CR/VGPR in the ASCT group demonstrated a greater OS time compared with non-ASCT patients (P=0.031). Relapsed patients who received bortezomib-based regimens did not demonstrate a longer survival time post-relapse compared with those who received non-bortezomib-based regimens (26.5 months vs. 10.5 months; P=0.271). The current study presented the clinical characteristics of MM patients who were initially treated at the Beijing Chaoyang Hospital. Bortezomib-based regimens and ASCT were able to improve the OS of MM patients.